Trump's 200% tariff plan may be a bitter pill for US consumers, warns Dr Reddy's

The United States plans significant tariffs on imported generic medicines. These duties will rise to 200% in the coming years. Dr Reddy's Laboratories anticipates higher medicine prices for American consumers. Shifting manufacturing to the US is currently considered impractical by the company. In...

First seen 2h ago · latest update 2h ago · India · business

Developing: this story surfaced recently from a single outlet. It appears early by design — expect the confidence score to move as more outlets report (or don’t).